Phylogenetic polymorphisms in antibiotic resistance genes of the mycobacterium tuberculosis complex

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1205-1210

  Feuerriegel, Silke ^a,b   Köser, Claudio U ^c,d   Niemann, Stefan ^a,b  

^a Molecular Mycobacteriology   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Bedaquiline; Sequence analysis; Single nucleotide polymorphisms

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AHPC GENE; ANTIBIOTIC RESISTANCE; ARTICLE; ATPE GENE; BACTERIAL GENE; BACTERIAL STRAIN; DDN GENE; EMBA GENE; EMBB GENE; EMBC GENE; FGD1 GENE; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GIDB GENE; GYRA GENE; INHA GENE; KATG GENE; MSHA GENE; MYCOBACTERIUM; MYCOBACTERIUM AFRICANUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM CANETTII; MYCOBACTERIUM CAPRAE; MYCOBACTERIUM MICROTI; MYCOBACTERIUM PINNIPEDII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENY; PNCA GENE; RPOB GENE; RPSA GENE; RPSL GENE; RRS GENE; SEQUENCE ANALYSIS; THYA GENE; TLYA GENE; DRUG EFFECTS; GENETICS; HUMAN;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENETIC VARIATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84898471871     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt535     Document Type: Article

References (20)

1. WHO. Global Tuberculosis Report 2013. http://apps.who.int/iris/ bitstream/10665/91355/1/9789241564656_eng.pdf (8 December 2013, date last accessed).
2. Köser CU, Bryant JM, Becq J et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369: 290-2.
3. Parrish N, Carrol K. Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis. Future Microbiol 2008; 3: 405-13.
4. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404.
5. Köser CU, Ellington MJ, Cartwright EJ et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 2012; 8: e1002824.
6. Köser CU, Feuerriegel S, Summers DK et al. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 2012; 56: 6080-7.
7. Mathys V, Wintjens R, Lefevre P et al. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53: 2100-9.
8. Feuerriegel S, Köser C, Trübe L et al. Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance. Antimicrob Agents Chemother 2010; 54: 4794-8.
9. Fivian-Hughes AS, Houghton J, Davis EO. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology 2012; 158: 308-18.
10. Wang Q, Yue J, Zhang L et al. A newly identified 191A/C mutation in the Rv2629 gene that was significantly associated with rifampin resistance in Mycobacterium tuberculosis. J Proteome Res 2007; 6: 4564-71.
11. Chakravorty S, Aladegbami B, Motiwala AS et al. Rifampin resistance, Beijing-W clade-single nucleotide polymorphism cluster group 2 phylogeny, and the Rv2629 191-C allele in Mycobacterium tuberculosis strains. J Clin Microbiol 2008; 46: 2555-60.
12. Homolka S, Köser C, Archer J et al. Single-nucleotide polymorphisms in Rv2629 are specific for Mycobacterium tuberculosis genotypes Beijing and Ghana but not associated with rifampin resistance. J Clin Microbiol 2009; 47: 223-6.
13. Louw GE, Warren RM, van Helden PD et al. Rv2629 191A/C nucleotide change is not associated with rifampicin resistance in Mycobacterium tuberculosis. Clin Chem Lab Med 2009; 47: 500-1.
14. Zhang JX, Wu XQ, Yang YR et al. Association among the Rv2629 gene, rpoB gene, RFP resistance and Beijing genotype in M. tuberculosis clinical isolates. Afr J Microbiol Res 2010; 4: 1575-80.
15. Ando H, Mitarai S, Kondo Y et al. Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol 2011; 60: 184-8.
16. Feuerriegel S, Köser CU, Bau' D et al. Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011; 55: 5718-22.
17. Feuerriegel S, Köser CU, Richter E et al. Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother 2013; 68: 1439-40.
18. Zhang S, Chen J, Shi W et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2013; 2: e34.
19. de Jong BC, Antonio M, Gagneux S. Mycobacterium review-africanum of an important cause of human tuberculosis inWest Africa. PLoS Negl Trop Dis 2010; 4: e744.
20. Segala E, Sougakoff W, Nevejans-Chauffour A et al. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012; 56: 2326-34.